Transcend Therapeutics ©
transcendtherapeutics.com
Actively hiring
Psychiatric Care
Health Care
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Backers
1
AlleyCorp
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
2021
Founded
Backed byfrom the funds' portfolios and accelerator catalogs
AlleyCorp Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Rapid-acting interventional psychiatry in San Antonio. Spravato (esketamine), coordinated care to remission, in-network with major Texas…
Metabolic Psychiatry Labs provides advanced mental health treatment using metabolic therapy and innovative psychiatry research.
Creating breakthroughs in mental health. We are on a mission to transform patient outcomes by developing rapid-acting, durable and…
Find trusted ketamine-assisted psychotherapy (KAP) therapists near you. Browse our directory, choose your provider, and get started with…
Stella Mental Health utilizeseffective treatments like Spravato (esketamine), Deep Transcranial Magnetic Stimulation (TMS),Stellate…
An Epic Leap For Mental Health. Developing innovative new chemical entities that transform the treatment paradigm of psychiatric disease —…
News
Transcend Therapeutics Announces Completion of Acquisition by Otsuka Pharmaceutical
June 12, 2026
Read more
Report
Transcend Therapeutics Receives FDA National Priority Voucher for TSND-201 in PTSD
New York, April 27, 2026 - Transcend Therapeutics, a clinical-stage biotechnology company developing rapid-acting treatments for neuropsychiatric conditions, announced that the U.S. Food and Drug Administration (FDA) has awarded the company a national pri
Read more
Report
Otsuka Pharmaceutical to Acquire Transcend Therapeutics
Expands Otsuka portfolio in psychiatric and neurological fields and aims to accelerate development of Transcend's portfolio, including the TSND-201 program for post-traumatic stress disorder (PTSD)
Read more
Report
JAMA Psychiatry
With the completion of the transaction, Transcend is now a wholly owned subsidiary of Otsuka America, Inc.
Read more
Report
IMPACT-1 Study Published in JAMA Psychiatry: Results of TSND-201 (Methylone) in Patients with Severe PTSD
NEW YORK, Feb. 18, 2026 - Transcend Therapeutics, a clinical-stage biotechnology company developing rapid-acting treatments for neuropsychiatric conditions, today announced the publication of IMPACT-1, a Phase 2 randomized, double-blind, placebo-controlle
Read more
Report
JAMA Psychiatry
NEW YORK, Feb. 18, 2026 Transcend Therapeutics , a clinical-stage biotechnology company developing rapid-acting treatments for neuropsychiatric conditions, today announced the publication of IMPACT-1, a Phase 2 randomized, double-blind, placebo-controlled
Read more
Report
New Data Demonstrating the Mechanism of Action of TSND-201 (methylone) for the Treatment of PTSD Published in Neuropsychopharmacology
NEW YORK, September 2, 2025 - Transcend Therapeutics, a clinical-stage biotechnology company developing rapid-acting treatments for neuropsychiatric conditions, today announced the publication of new preclinical data confirming the mechanism of TSND-201 (
Read more
Report
Transcend Therapeutics Receives Breakthrough Therapy Designation for TSND- 201 (methylone) for the Treatment of PTSD
New York, July 10, 2025 /PRNewswire/ - Transcend Therapeutics, a clinical-stage biotechnology company that develops medicines to treat neuropsychiatric diseases, today announced that the U.S. Food & Drug Administration (FDA) has granted Breakthrough Thera
Read more
Report
Transcend Therapeutics Presents Positive Phase 2 Results of the Placebo-Controlled IMPACT-1 Study of PTSD at American Society of Clinical Psychopharmacology (ASCP) Annual Meeting Supporting TSND-201 as a Rapid, Robust, and Long-Lasting Treatment for PTSD
Late breaking oral presentation of results from the positive IMPACT-1 Phase 2 placebo-controlled trial in PTSD IMPACT-1 met the primary endpoint, demonstrating statistically significant placebo-adjusted CAPS-5 improvement of -9.64 on Day 64 Results suppor
Read more
Report
TSND-201 (Methylone) as a Treatment for PTSD: Rapid, Robust, and Long-Lasting Activity in Phase 2
Summary of Presentation: TSND-201 is a non-hallucinogenic, rapid acting neuroplastogen that increases neurite outgrowth Preclinical results demonstrate rapid, robust, and long-lasting benefit tests of PTSD, anxiety, depression View Poster The post TSND-20
Read more
Report
Show more news